Kalshi is Betting on Trial Results and FDA Decisions Now, What's Next?
FDA Announces 3 Final Guidances to Increase Patient Participation in Oncology Trials
Evis Sala Announces a Landmark Oncology Partnership Between Albania and Italy
First Chemotherapy Session: What to Expect
Herbert Loong: Prospective Open-labelled Phase 2 Pembrolizumab in Acral Lentiginous Melanoma
SABCS 2026 Male Breast Cancer Advocate Scholarship
Wafik El-Deiry: Scientific Freedom and Diverse Thinking Drive Better Medicine
RxPONDER Analysis: Ovarian Reserve May Refine Chemotherapy Decisions in HR-Positive Breast Cancer
Tracks cumulative cisplatin exposure (mg/m²) and shows evidence-based risk flags for ototoxicity and renal injury.
Can be calculated from BSA calculator
Pediatric thresholds: ≥360 mg/m² higher risk
Risk Thresholds:
